BridgeBio Pharma

BBIO · NASDAQ

$67.55−$0.39 (−0.57%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $67.94

Latest news

Press releaseOct 16, 7:30 AM ETGlobe Newswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 11, 2:30 PM ETGlobe Newswire
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
Press releaseOct 11, 11:42 AM ETGlobe Newswire
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1
Press releaseOct 6, 4:01 PM ETGlobe Newswire
BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026
Press releaseOct 6, 4:01 PM ETGlobe Newswire
BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting
Press releaseOct 6, 12:57 PM ETPRNewswire
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
Press releaseOct 6, 7:30 AM ETGlobe Newswire
BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia
Press releaseOct 5, 4:01 PM ETGlobe Newswire
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
Press releaseOct 5, 7:30 AM ETGlobe Newswire
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
Press releaseSep 23, 7:47 AM ETGlobe Newswire
Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
NewsSep 9, 10:33 AM ETVandana Singh
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
NewsSep 1, 4:57 AM ETNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Press releaseAug 10, 4:01 PM ETGlobe Newswire
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
NewsAug 9, 8:01 AM ETPiero Cingari
Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This Week
NewsJul 10, 11:30 AM ETVandana Singh
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
Press releaseJun 22, 9:05 AM ETGlobe Newswire
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
Press releaseMay 12, 8:30 AM ETPRNewswire
Wall Street's Cardiac Bet: Where Diagnostics Meet the Money
Press releaseMay 7, 4:01 PM ETGlobe Newswire
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
Press releaseApr 28, 7:30 AM ETGlobe Newswire
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
NewsMar 10, 2:49 PM ETVandana Singh
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
NewsFeb 24, 4:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsFeb 24, 4:04 PM ET
BridgeBio Pharma Earnings Review: Q4 Summary
Press releaseFeb 24, 4:01 PM ETGlobe Newswire
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
NewsFeb 24, 6:11 AM ET
Earnings Scheduled For February 24, 2026
NewsFeb 23, 10:02 AM ET
Insights Ahead: BridgeBio Pharma's Quarterly Earnings
NewsFeb 12, 12:44 PM ETVandana Singh
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026
NewsDec 31, 10:01 AM ETNamrata Sen
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
NewsDec 11, 7:33 AM ETAvi Kapoor
This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
NewsNov 14, 12:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
Press releaseOct 29, 4:01 PM ETGlobe Newswire
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
NewsOct 29, 2:22 PM ETVandana Singh
BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder
NewsOct 29, 7:11 AM ET
Earnings Scheduled For October 29, 2025
NewsOct 28, 5:13 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsOct 28, 12:01 PM ET
Earnings Outlook For BridgeBio Pharma
NewsOct 24, 4:03 PM ET
BridgeBio Pharma To Host Webinar On Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results On October 27, 2025 At 8:00am ET
NewsSep 29, 10:42 AM ETVandana Singh
BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition
NewsSep 11, 2:47 PM ET
'BridgeBio Says Pfizer, Alnylam Aren't Playing Fair in Blockbuster Race'- Bloomberg
Press releaseAug 5, 4:01 PM ETGlobe Newswire
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsJul 30, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
NewsJul 15, 1:35 PM ET
10 Health Care Stocks Whale Activity In Today's Session
Press releaseJun 12, 2:41 PM ETBusiness Wire
BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types
Press releaseApr 29, 4:01 PM ETGlobe Newswire
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
NewsApr 28, 3:01 PM ET
A Look Ahead: BridgeBio Pharma's Earnings Forecast
Press releaseApr 28, 5:00 AM ETGlobe Newswire
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
Press releaseApr 23, 11:00 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)
Press releaseApr 22, 7:30 AM ETGlobe Newswire
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
Press releaseApr 1, 8:00 AM ETBusiness Wire
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors
Press releaseFeb 20, 7:30 AM ETGlobe Newswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
Press releaseNov 12, 7:30 AM ETGlobe Newswire
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
Press releaseAug 1, 7:30 AM ETGlobe Newswire
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records

Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening

BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

Earnings Volatility Watch: Applied Materials and 10 Other Stocks Could See Double-Digit Moves This Week

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

12 Health Care Stocks Moving In Tuesday's After-Market Session

BridgeBio Pharma Earnings Review: Q4 Summary

BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

Earnings Scheduled For February 24, 2026

Insights Ahead: BridgeBio Pharma's Quarterly Earnings

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

10 Health Care Stocks With Whale Alerts In Today's Session

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder

Earnings Scheduled For October 29, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session

Earnings Outlook For BridgeBio Pharma

BridgeBio Pharma To Host Webinar On Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results On October 27, 2025 At 8:00am ET

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition

'BridgeBio Says Pfizer, Alnylam Aren't Playing Fair in Blockbuster Race'- Bloomberg

BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates

Earnings Scheduled For August 5, 2025

10 Health Care Stocks Whale Activity In Today's Session

10 Health Care Stocks Whale Activity In Today's Session

BBOT Announces Publication in Science Highlighting Preclinical Data that Supports the Potential for RAS:PI3Kα Breaker BBO-10203 to Provide Therapeutic Benefit across Multiple Tumor Types

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

A Look Ahead: BridgeBio Pharma's Earnings Forecast

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor, in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update